Our main hypothesis is to consider that the detection of biomarkers on admission combined with the length of the cervix would improve the prediction of the latency period in case of preterm premature rupture of membranes (pPROM). The primary purpose of the protocol is to assess the performance of these tests to predict a latency period \<48 hours in case of pPROM.
Preterm premature rupture of membranes (pPROM) is defined as a spontaneous rupture before the start of labor ("premature" rupture) and before 37 weeks of gestation ("preterm"). pPROM concern 2-3% of pregnancies. It is the main cause of prematurity since it is responsible for 24 to 42% of preterm deliveries. The time between PROM and childbirth is named the latency period. Its total duration can vary from a few hours to several weeks. Childbirth occurs within 48 hours of rupture for 18 to 93% of cases, within 7 days for 56 to 96% and within 28 days for 78 to 100%. The earlier PROM occurs during pregnancy, the longer the latency period is. The factors associated with a shorter latency period are: cervical changes during admission for pPROM, a shortened cervix on ultrasound or a threat of premature delivery prior to PROM, the existence of uterine contractions, oligoamnios, and the occurrence of a materno-fetal complication of pPROM. In a pPROM situation, a prolonged latency period improves the neonatal prognosis by increasing the gestational age of birth, gives the possibility of administering the corticosteroid treatment of fetal pulmonary maturation and also allows an in utero transfer in an adapted maternity. Several studies have shown a correlation between the length of the cervix during rupture and the latency period in the context of pPROM. To date, there are no effective biomarkers used in current practice to predict this latency period. We want to assess the diagnostic performance of different vaginal (PIBF / PP14 / IGFBP1 native and total) and serum (PIBF / MIF) markers as well as the ultrasound length of the cervix to predict the duration of this latency period in order to better anticipate the risk of prematurity.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
170
Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and sent to the laboratory for subsequent analysis of biomarkers (IGFBP1 T/N, PIBF, PP14) and storage.
2 tubes of blood sample were collected and sent to the laboratory for serum storage and biomarkeurs assay (PIBF and MIF)
CHU de Clermont-Ferrand
Clermont-Ferrand, France
RECRUITINGtotal IGFBP1 in vaginal secretion at admission
Results of the tests detecting total IGFBP1 (positive/ negative)
Time frame: Day 0
native IGFBP1 in vaginal secretion at admission
Results of the tests detecting native IGFBP1 (positive/ negative)
Time frame: Day 0
PP14 in vaginal secretion at admission
PP14 values in vaginal secretion at admission dosed using the ELISA technique
Time frame: Day 0
PIBF in vaginal secretion at admission
PIBF values in vaginal secretion at admission dosed using the ELISA technique
Time frame: Day 0
PIBF in maternal serum at admission
PIBF values in maternal serum at admission dosed using the ELISA technique
Time frame: Day 0
MIF in maternal serum at admission
MIF values in maternal serum at admission dosed using the ELISA technique
Time frame: Day 0
Ultrasound length of cervix measured at the admission
Length of cervix was maesured by ultrasound at the admission (millmeters)
Time frame: Day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.